

PROLIGHT DIAGNOSTICS DELIVERS ON SBRI HEALTHCARE GRANT

Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has successfully completed the SBRI Healthcare phase 2 award, accelerating development of its unique digital immunoassay.

Psyros received the SBRI Healthcare phase 2 grant of approximately 1 million GBP last year, requiring the completion of certain milestones. Psyros has now met or exceeded all the milestones and work packages set out in the agreement, including developing a research level fully functional prototype of the single molecule counting instrument. The six prototype units will serve to accelerate the development of the reagent cartridge and to define the requirements for the development of a commercially viable platform.

“The SBRI Healthcare awards help the NHS to develop new technologies and solutions to address some of the biggest healthcare challenges facing society. We have selected these innovations because they have the potential to make a big difference to patients. By supporting the most promising innovations the NHS will continue to evolve, helping meet more patients’ needs and encouraging more innovators to come forward with ideas that make a difference,” said Matt Whitty, CEO of the Accelerated Access Collaborative (AAC), an initiator of SBRI Healthcare.

“The SBRI grant has not only allowed us to accelerate the development of the concept of the digital immunoassay but has also been a way for us to measure ourselves against other technologies and we are very happy for this acknowledgement. This puts us in a good position to bring a high-sensitive troponin assay to the market,” said Ulf Bladin, CEO of Prolight Diagnostics.

About SBRI Healthcare

SBRI Healthcare is an Accelerated Access Collaborative (AAC) initiative, supported by the Academic Health Science Networks (AHSNs) and managed by LGC Group. SBRI Healthcare aims to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice. Since 2008, the NHS has backed the SBRI programme, supporting over 200 companies to develop innovative technologies that match the needs of the health service. Many of these are now selling into global markets and delivering innovation to the healthcare community. Previous SBRI Healthcare competitions have called for technological and innovative solutions to, for example, change people’s behaviour in order to reduce the impact of obesity and alcohol related diseases, how to live well with dementia and improved medicine management. www.sbrihealthcare.co.uk

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: ub@prolightdiagnostics.se

Telephone: +46 73 582 39 87

Website: www.prolightdiagnostics.se/en/

About Us

Prolight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible near-patient testing systems, Point-of-Care Testing (POCT), which is IT based on patented technology. POC tests are performed outside the traditional hospital laboratory with small mobile instruments in health centres, nursing homes, emergency departments, intensive care units, and other settings, enabling testing close to the patient and with rapid test results. With this technology, health care providers will be able to sort out patients in need of rapid treatment from patients that, for example, are not having a heart attack. The sales value in the POCT area amounted to USD 34.6 billion in 2021 and is growing strongly.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight Diagnostics Delivers on SBRI Healthcare Grant